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Abstract:
Localized Aggressive Periodontitis (LAgP) is an aggressive, early onset form of
periodontitis characterized by a unique niyeloid cell phenotype. In addition to its
bacterial origin, the unique phenotype of the myeloid cell contributes to disease
pathogenesis and progression through mechanisms mediating host inflammatory and
immune responses. LAgP monocytes synthesize increased levels of the potent
proinflammatory lipid mediator, Prostaglandin E2 (PGE2), preferentially differentiate into
dendritic cells, and lead to increased IgG2 production. In addition, levels of Platelet
Activating Factor (PAF) have shown to be elevated in the gingival tissue and gingival
crevicular fluid of subjects with periodontitis. The aim of this study was to further
characterize the unique phenotype of the myeloid cell by investigating its role in the
increased levels of PAF in periodontitis subjects, examining differences in gene
expression of the immune response gene, STATl which is involved in IFN-y signaling,
and by examining the differential expression and function of the scavenger receptor

CD36. LAgP monocytes have exhibited decreased activity of the PAF-acetylhydrolase
(PAFAH), the catalytic enzyme that breaks down PAF. Since PAF levels are regulated
by synthesis and degradation, we hypothesized that synthesis by myeloid cells,
monocytes or PMN, also contribute to the increased PAF levels in LAgP. We also
hypothesized, based on initial microarray data that myeloid cells have decreased gene
expression of STATl and downstream IFNy related genes in LAgP. In addition, based
on the initial microarray results, we hypothesized that LAgP monocytes have increased

CD36 expression with increased capacity for the binding and uptake of chemically
modified versions of LDL. Monocytes were isolated from the peripheral blood of LAgP

and NP control subjects over a Ficoll gradient. A radiolabeled PAF assay was used to
quantify total PAF synthesis in both resting monocytes and PMN, and in monocytes and
PMN stimulated with calcium ionophore A23 187. Quantitative RT-PCR was used to
quantify STATl and CD36 gene expression from RNA isolated from adherent
monocytes, and CD36 expression and AcLDL (acetylated LDL) uptake was quantified
using flow cytometry. Our results indicate that PAF synthesis is increased in LAgP PMN
but not in monocytes. LAgP monocytes synthesize less PAF compared to NP control,
and their response to calcium ionophore A23 187 (IoA), expressed as fold increase, was
blunted. LAgP and NP monocytes did not differ in STATl gene expression as
determined by quantitative RT-PCR, and CD36 experiments suggest the possibility that
dendritic cells express increased scavenger receptor CD36 than macrophage cells. In
conclusion, LAgP myeloid cells are unique in their response to A23 187, and LAgP PMN
contribute to increased PAF primarily through synthesis, whereas the LAgP monocyte
contributes to elevated PAF through decreased catabolism. STAT 1 gene expression did
not differ between LAgP and NP monocytes, however this does not rule out the
possibility of differential STATl signaling in LAgP monocytes though inhibitory
proteins or differential phosphorylation of STATl. Finally, CD36 expression appears
from preliminary data to be increased in dendritic cells. These findings add to the current
understanding of the unique phenotype of the LAgP monoctye and further experiments
will continue to expand our understanding of how unique biology of myeloid cells and
their ability to facilitate crosstalk between the innate and adaptive immune system, and
the host inflammatory system.

General Introduction:

Localized Aggressive Periodontitis (LAgP) is an early onset form of periodontitis
characterized by the aggressive destruction of the gingival tissues, the supporting
periodontal ligaments, and the alveolar bone (1,2). LAgP is a subset of periodontal
disease characterized by juvei~ileonset and localized disease involving only the
permanent incisors and first molar teeth (83, 84). Support for a genetic basis comes from
an observed greater prevalence in the African American population and from a known
familial disease distribution (8 1,82).
LAgP is known to have a bacterial etiology with infection of the gingival tissues
caused by several bacterial pathogens, most commonly Actinobacillus

actinomycetemcomitans (A.a.) and Porphyromonas gingivalis (P.g.) (3,4). However, in
addition to this bacterial etiology, the host innate immune system and host inflan~matory
response are also implicated in the pathogenesis and the progression of LAgP. The host
innate immune response can respond through the activation of sentinel immune cells,
activation of phagocytic cells, and the synthesis and release of soluble mediators to
provide the initial protective and more specific adaptive host immune response.
Concurrently, the host's inflammatory system becomes activated and is upregulated in
response to pathogens and the danger signals they provide. Such activation results in
protective and destructive effects on the overall health of the underlying gingival tissue,
and ultimately perpetuates the chronic, progressive nature of disease observed in LAgP.
An example of a protective immune response in LAgP subjects is the enhanced IgG2
production observed in these subjects (5-7). Increased levels of protective IgG2 antibody
are promoted by LAgP monocytes and have been shown to correlate with reduced disease

severity (5-7). However in LAgP, the same myeloid cells responsible for generating this
protective response also synthesize increased levels of the pro-inflammatory lipid, PGE2.
In this way, monocytes play a central role in mediating both protective immune and
destructive pro-inflammatory responses to this disease.
Our hypothesis is that within healthy, non-periodontitis subjects, myeloid cells
achieve a balance between host protective and proinflammatory effects that favors
disease resolution and eradication. In contrast, we hypothesize that LAgP subjects have
enhanced immune and proinflammatory signals that result in increased priming of
immune cells to respond danger signals and increased proinflammatory signals that are
not turned off in time to prevent tissue destruction. In LAgP subjects, the monocyte
displays a very unique phenotype with the aforementioned induction of increased IgG2
production, (1 1) preferential differentiation into dendritic cells (12), increased production
of the proinflammatory lipid PGE2, and decreased activity of platelet-activating factor
acetylhydrolase (PAF-AH) (24). Together, these data suggest that many features of this
unique host response in LAgP subjects are due to the distinct biology of the LAgP
myeloid cells. Therefore, monocyte modulation of the host immune and inflammatory
response has a significant impact on disease pathogenesis and progression in LAgP and
provides a key link between the innate and adaptive immune systems, and the
inflammatory system. Understanding these links is likely to provide increased insight
into the biology of LAgP and possibly other chronic inflammatory diseases.

Chapter 1: STATl Expression in LAgP and NP Monocvtes

A possible mechanism for monocyte modulation of LAgP may be via altered
expression of immune response genes, such as IFN-gamma. LAgP is a chronic
inflammatory disease driven by host Thl imm~lneresponses and associated with elevated
interferon gamma (IFN-y). IFN-y is produced by activated NK (natural killer) cells,
activated Thl cells, and, in the presence of IL-12 and IL- 18, by activated DCs (dendritic
cells) and macrophages (60). IFN signaling plays a key role in host defense against
bacteria and integrates early, innate responses with later, adaptive immune responses.
The biological responses to IFN-y, such as activation of niacrophages, are mediated by
regulation of gene expression.
IFN-y signals through the Jak-STAT 1 (signal transducer and activator of transcription

1) pathway; this results in the majority of effects of IFN-y on Thl immunity (61). The
STAT family of transcription factors regulates the expression of genes involved in the
diverse cellular processes of proliferation, differentiation, survival, and apoptosis. Seven
family members have been identified so far, and can be fo~lndlocated in the nucleus or
cell cytoplasm. The key function of these transcription factors is to translate signals
generated at cell surface receptors to the nucleus to regulate the gene expression of
specific target promoters.
STAT1 is the major effector of IFN-y signaling. The receptor for IFN-y structurally
consists of 2 subunits, the IFN-y receptor 1 (IFNGR1) and IFNGR2 chains, which
associate with JAKl and JAK2 kinases (56). Binding of IFN-y to its receptor induces
oligomerization and activation of the receptor associated Janus kinases, Jakl and Jak2 by
transphorylation (56). The activated JAK112 kinases phosphorylate the intracellular

domain on tyrosine 440 on human IFNGRl, which serves as a docking site for STATl.
STATl binds to IFNGRl and is phosphorylated on a conserved COOH-terminal tyrosine
residue 701(56). In addition to this phosphorylation event, during the early phase of
activation, STATl is also phosphorylated on serine 727 by a process involving

phosphatidylinositol3-kinase and Akt (88). This second phosphorylation on S727 is
required for maximal transcriptional activity (89). These phosphorylation events activate
STATl to undergo homo-dimerization through Src-homology-2 (SH2) domains (62).
STATl homodimers then translocate to the nucleus and regulate gene expression by
binding to target sequences of promoters containing IFN-y -activated site (GAS) elements
(62).
Microarray (defined as a high-density array of oligonucleotides or cDNAs on silicone
chips or glass slides providing a means to monitor changes in the level of expression of
thousands of transcripts simultaneously in response to a variety of stimuli), was
performed on peripheral blood monocytes from LAgP and NP subjects. The preliminary
results suggested differential gene expression of STATl and other IFN-y related genes in
LAgP subjects compared to NP control (Table 1). Of importance, in addition to STATl,
several genes downstream of IFN-y also exhibited decreased expression (Table I). These
preliminary microarray data led us to consider STATl and its role in immune response in
LAgP monocytes, particularly with regard to IFN-y signaling. Given the chronic nature of
LAgP, we hypothesized that decreased STATl levels would dampen IFN-y signaling and
result in decreased IFN-y effector function and limited host response against oral bacteria.
In this way, decreased STATl signaling would limit the induction of inflammatory and

cell mediated immune responses in LAgP monocytes, thus interfering with host ability to
reduce bacterial load and perpetuate a chronic disease state.

Figure 1: Interferon signaling via JAK-STAT pathways from Decker et al. (58).

I

TAT 1

Intracellular signaling pathways for both type I and type I1 interferons. Interferon y binds
to its receptor composed of two subunits, IFNGRl and 2. IFNGRl and 2 are associated
with Janus kinases (Jakl and Jak2, also Tyk2). Phosphorylation of IFNGR leads to
recruitment and phosphorylation of STATl by the JAKs, followed by homodimerization
of STATl, translocation to the nucleus, binding to target GAS sequences and initiation of
the transcription of target genes.

Table 1:
Decreased Expression of STATl and IFN-)IRelated Genes in LAgP Monocytes
Accession # Gene
NM-0073 15 STAT 1

Fold Change
-2.5

SE
0.2

Frequency
4

NM-0064 17 Interferon-induced 44
protein

-5.8

1.7

5

NM-0168 16 Oligoadenylate synthease

-6.5

2.0

5

BC002666

-2.1

0.1

4

NM-005 101 Interferon a-induced protein
G1P2

-3.3

0.3

4

NM-002462 Myxovirus resistance protein

-3.2

0.4

4

NM-00 1549 interferon-induced protein 4
with tetratricopeptide repeats

-2.8

0.5

4

Interferon-induced guanylate
binding protein

Data table of genes differentially expressed in monocytes isolated from 3 LAgP and 3 age
and race matched NP control subjects. Fold change describes the fold decrease in nil2NA
expression of the gene listed in LAgP monocytes. SE is the standard error, and frequency
describes the number of subjects analyzed. Decreased STATl expression was observed
when each NP was matched to each LAgP subject. Accession number is also listed.

Materials and Methods:
Human subjects: Human studies were performed in compliance with all relevant federal
guidelines and the institutional policies of Virginia Commonwealth University. All
subjects were obtained by the Clinical Research Center for Periodontal Disease, School
of Dentistry, Virginia Commonwealth University, Richmond, Virginia. Patients with
Localized Aggressive Periodontitis (LAgP) had localized pattenis of severe periodontal
destruction limited to the first molars and incisors with involvement of up to 2 additional
teeth. Generalized Aggressive Periodontitis (GAgP) subjects had at least 8 teeth affected
by 5 mm or more of attachment loss, at least three of which were not molars or incisors.
Both subsets of aggressive periodontitis subjects had evidence of disease onset before age
35. Chronic periodontitis (CP) subjects had at least 2 mm attachment loss on more than
one tooth, disease onset after age 30, and no evidence of rapid loss of attachment. The
Non-Periodontitis (NP) control subjects were age and race-matched to the periodontitis
subjects. NP subjects had no evidence of attachment loss, except for recession on the
buccal surface of anterior teeth at no more than one site, and no pockets with a depth
greater than 3 mm. All subjects were African American and non-smokers. NP controls
were age and race-matched with periodontitis subjects.

Isolation of monocytes from peripheral blood: 30 ml of heparinized human peripheral
blood was added to 20 ml RPMI; 25 ml of that suspension was layered over 20 ml of
Lymphocyte Separation Media (MP Biomedicals, Aurora, OH), and centrifuged at 400 x
g for 30 min. Peripheral Blood Leukocytes (PBL) were then collected from the interface
and washed 3 times with sterile RPMI. Adherent monocytes were obtained by culturing

lo7 PBLi well in 1 ml of RPMI on plastic 6-well plates for 1 hr at 37OC, 5% C02. After
the incubation, non-adherent cells were removed through extensive washing of the
adherent monolayer with RPMI. Adherent monocytes were then used for RNA
extraction.

RNA extraction: RNA was extracted using Trizol LS reagent with 750 p1/107 cells.
RNA was dissolved in microbiology grade DNaseiRNase free H20 and stored in -80
degrees Celsius until used for quantitative RT-PCR (Reverse Transcriptase-Polymerase
Chain Reaction). Total RNA concentration was determined by OD values using a
Beckman DU 640 Spectrophotometer. Absorbance at 260 and 280 nm was measured and
the total RNA concentration was calculated. Purity was determined using the
A260iA280 ratio. Only samples with an A260iA280 ratio above 1.4 were used for
subsequent gene expression experiments.

Quantitative RT-PCR: RNA was extracted using Trizol LS and used for quantitative
RT-PCR. The protocol used for STATl was 48 degrees C for 30 minutes followed by
heating to 95 d
egrees C for 9 minutes, followed by 40 cycles of 95 degrees C for 15 seconds and 60
degrees C for 1 minute. Data were normalized to internal control 18S, the ribosomal
RNA. STAT1 primers and probes were obtained from Integrated DNA Technologies.
Sequence of Primers and Probes were as follows:
STATl sense: 5'

- AGT

STATl antisense: 5'

ACC TGG CAC AGT GGT TAG A -3'.

- AAC

GGA TGG TGG CAA ATG AAA C -3'.

STAT1 Probe: 5' - / 56 FAMITTG GCA GCG TGC TCC CAG TCT TGC / 3BHQ-11-3'.
18s sense: 5' - AAA ATT AGA GTG TTC AAA GCA GGC -3'.
18s antisense: 5'- CCT CAG TTC CGA AAA CCA ACA A -3'.
18s probe: 5' - /5Cy5/CGA GCC GCC TGG ATA CCG CAG C /3BHQ-21 -3'.

Results:
We hypothesized that STAT1 expression would be decreased in our LAgP subjects
and follow the trend predicted by the microarray data (Table 1). To address this question,
we quantified the level of STAT1 mRNA in monocytes isolated from the peripheral
blood of NP and LAgP subjects. NP subjects were age and race matched with LAgP
subjects. Total RNA from monocytes isolated from PBL (peripheral blood leukocytes)
by adherence to a plastic 6 well culture plate was isolated using Trizol LS. RNA purity
was determined using the spectrophotometer, and only RNA with a purity greater than
1.4 was used for subsequent gene expression studies. Quantitative RT-PCR was
performed on NP and LAgP samples, and data was normalized to 18s expression to
account for differences in total RNA in each sample. A total of 6 NP and 8 LAgP
subjects were analyzed. Samples were run in duplicates and triplicates when possible.
There was no statistically significant difference in the level of STAT1 mRNA expression
by LAgP monocytes compared to NP monocytes (Figure 2).

Figure 2: STATl mRNA expression in freshly isolated LAgP and NP monocytes

LAgP
N=6

STATl mRNA levels were analyzed using quantitative RT-PCR. RNA was isolated
from the peripheral blood of monocytes from LAgP and NP control subjects. N is the
number of subjects used for each subgroup. Data are expressed as relative STATl
mRNA expression and are normalized to 18s expression. There is no difference in
STATl gene expression in the LAgP and NP population tested.

Discussion:
LAgP is a chronic inflammatory disease driven by host Thl immune responses, and
more specifically through activation and signaling of the interferon gamma (IFN-y)
dependent target cells of the myeloid lineage. The results of the microarray experiments
differ from our RT-PCR experiments quantifLing gene expression levels of STAT 1 in
LAgP and NP monocytes. There are several possible explanations for this difference.
Differences in the microarray and quantitative real time PCR experiments might be
due to subject-to-subject variability inherent in patient studies conducted with a small
sample size, and may be related a small sample size used for the microarray. Differences
in method of monocyte isolation were also initially thought to account for the conflicting
result. The microarray data was generated using monocytes isolated by MACS
(Magnetic Activated Cell Sorting), whereas the quantitive RT-PCR experiments utilized
monocytes isolated from PBL by adherence and washing. The MACS isolation method
results in a much purer population of monocytes, whereas other leukocytes such as T and
B lymphocytes would still be present in the adherent cell preparation. Since STATl is
ubiquitously expressed in cells of the immune system, RNA isolated from adherent cells
would contain STAT1 mRNA expressed from these other non-monocyte cells.
However, subsequent experiments in monocytes isolated by MACS did not yield a
difference in STATl mRNA expression (data not shown).
Finally, several proteins that interact with STATl and modulate its transcriptional
activity have been identified. Examples of such STATl regulatory proteins include
CREB-binding protein (CBP/p300), mini-chromosome maintenance protein 5 (MCM5)
and breast cancer susceptibility gene 1 (BRCA1) (85-87). It is possible one of these or

an as yet unidentified inhibitor of STAT1 transcription exists in some LAgP and NP
subjects but not in others. It remains possible that differences in IFN-y signaling may
still be observed in LAgP and NP subjects that are a result of differential regulation of
STAT1 inhibitory proteins or differences in levels of serine or tyrosine phosphorylation
in LAgP and NP monocytes.
Interestingly, Ramana et al. have recently reported that activation of IFN-y target
promoters can be stimulated even in the absence of STAT1 (57). This would suggest
that decreased STAT 1 may not result in decreased expression of target genes as long as
IFN-y promoters can still be stimulated as suggested by Ramana et a1 (57). In addition,
Decker et a1 reported that bacteria and bacterial products can directly influence the ability
of STAT1 to act as a transcription factor (49). For full activity, STATl must be
phosphorylated at both the Y701 and S727 site located in the carboxy-terminal
transactivation domain. Bacteria are capable of stimulating STATl S727
phosphorylation via p38 MAPK, and thus prime STAT1 for transcription factor activity
following IFN-stimulated tyrosine phosphorylation (49). However, like anything else in
biology, timing and duration of this event is critical. A prolonged encounter of
macrophages with bacteria leads to the synthesis of suppressors of cytokine signaling
(SOCS), proteins that can block the action of specific STATs and decreases their ability
to function as signaling molecules (63, 64). The duration of the bacterial stimulus on
macrophages appears critical in determining whether IFN-y signaling and subsequent
transcriptional activity in these cells. It is possible that the prolonged exposure to
microbacterial products in LAgP may limit the ability of IFN-y to signal and activate host
immune defenses. Other factors in addition to STATl gene expression can modify IFN-y

signaling and impact its effector f~~nction.
Further experiments are needed to elucidate if
differential STAT1 expression and function exists in LAgP and NP monocytes.

Chapter 2: Differential PAF Synthesis by LAgP Monocytes and PMN
Introduction:

In addition to bacterial etiology, host immune and inflammatory factors are implicated
in the pathogenesis and progression of LAgP. For example, increased protective immune
responses have also been observed in LAgP subjects as demonstrated by the enhanced
IgG2 responses to oral pathogens that correlate with reduced severity of disease (5-7). In
contrast, the polymorphonuclear neutrophils (PMN) of LAgP subjects exhibit impaired
chemotaxis that may exacerbate the disease (8,9), although recent studies suggest that
LAgP PMN are "hyperfunctional" in other respects (10). In addition, LAgP monocytes
display a unique phenotype that promotes IgG2 production (1 1) and predisposes these
cells to differentiate into dendritic cells (12). Together, these data suggest that the unique
host response of LAgP subjects can be traced to the distinct phenotypes of their myeloid
cells.
Differential synthesis and degradation of immune response mediators by myeloid cells
could impact the progression and severity of LAgP. One such biologically relevant
mediator is Platelet-Activating Factor, PAF (I-0-alkyl-2-acetyl-sn-glycero-3phosphocholine), a pro-inflamn~atoryphospholipid. PAF is synthesized primarily by
monocytes, PMN, and endothelial cells through a remodeling pathway (13- 15) and
targets a variety of cells through its G-protein coupled receptor (16). Upon ligand
binding, the PAF-receptor mediates diverse biological processes ranging from cell
adhesion, differentiation, angiogenesis, neurotransmission, to effects on reproductive and
cardiac biology, allergy, and sepsis among others. PAF levels in gingival crevicular
fluid (GCF) and saliva correlate directly with the severity of periodontal disease and

decline with successful treatment of disease (17-2 1). PAF induces the inflammatory
response in LAgP subjects by activating monocytes to produce the Thl- associated
cytokines, IL-12 and IL-18 (22). In addition, PAF acts directly on LAgP lymphocytes to
elicit IFN-)I, the prototypic, proinflammatory Thl cytokine (22). As inflammation plays
a major role in the pathogenesis of periodontal disease, these studies suggest that PAF
exacerbates disease. However, PAF also elicits the cytokines associated with protective
IgG2 antibody responses that correlate with reduced disease severity (23). Thus, the
biology of PAF is complex and this mediator can mediate both protective and destructive
effects.
Both catabolisnl and synthesis contribute to the overall level of PAF, and we
hypothesize that the increased PAF observed in LAgP subjects is secondary to both
reduced catabolisnl by the catabolic enzyme PAF acetylhydrolase (PAFAH) and
increased synthesis by monocytes or PMN, the leukocytes that synthesize PAF. In a
previous study, we demonstrated decreased PAFAH activity in LAgP monocytes
compared to monocytes of control subjects (24). The difference in PAFAH activity
correlated with the propensity of LAgP monocytes to differentiate into dendritic cells

(DC), which have low levels of PAFAH (12,24). The current study was intended to
elucidate the role of synthesis in determining PAF levels in LAgP subjects and to assess
the contributions of monocytes and PMN to the elevated PAF levels observed in LAgP
subjects.

Materials and Methods:
Human subjects: Human studies were performed in compliance with all relevant federal
guidelines and the institutional policies of Virginia Commonwealth University. All
subjects were obtained by the Clinical Research Center for Periodontal Disease, School
of Dentistry, Virginia Commonwealth University, Richmond, Virginia. Patients with
Localized Aggressive Periodontitis (LAgP) had localized patterns of severe periodontal
destruction limited to the first molars and incisors with involvement of up to 2 additional
teeth. Generalized Aggressive Periodontitis (GAgP) subjects had at least 8 teeth affected
by 5 mm or more of attachment loss, at least three of which were not molars or incisors.
Both subsets of aggressive periodontitis subjects had evidence of disease onset before age
35. Chronic periodontitis (CP) subjects had at least 2 mm attachment loss on more than
one tooth, disease onset after age 30, and no evidence of rapid loss of attachment. The
Non-Periodontitis (NP) control subjects were age and race-matched to the periodontitis
subjects. NP subjects had no evidence of attachment loss, except for recession on the
buccal surface of anterior teeth at no more than one site, and no pockets with a depth
greater than 3 mm. All subjects were African American and non-smokers.

Isolation of monocytes from peripheral blood: 30 ml of heparinized human peripheral
blood was added to 20 ml RPMI and 25 ml of that suspension was layered over 20 ml of
Lymphocyte Separation Media (MP Biomedicals, Aurora, OH), and centrifuged at 400 x
g for 30 min. Peripheral Blood Leukocytes (PBL) were then collected from the interface
and washed 3 times with sterile RPMI. Adherent monocytes were obtained by culturing
10' PBLI well in 1 ml of RPMI on plastic 6-well plates for 1 hr at 37OC, 5% C02. After

the incubation, non-adherent cells were removed through extensive washing of the
adherent monolayer with RPMI. Adherent monocytes were metabolically labeled and
PAF synthesis quantified as described below.

Isolation of PMN from peripheral blood: PMN were separated by a method described
by Scott-Zaki et a1 (25). Briefly, 30 ml of peripheral blood was collected in heparinized
syringes. PMN were separated by layering the blood over a gradient of Ficoll-Hypaque
at densities of 1.077 and 1.119 (Sigrnd Aldrich, St. Louis, MO). The tubes were then
centrifuged at 250 x g for 10 minutes, rotated 180" and centrihged for an additional 10
minutes. The PMN, which sedimented at the 1.119 interface, were collected without
disturbing the red blood cell pellet layer directly below. PMN were washed with HBSS
containing 0.1% BSA and 0.01M EDTA and further separated over a second identical
Ficoll-Hypaque gradient. The PMN were collected from the 1.119 interface, washed
with HBSS-BSA and EDTA solution, then used for the PAF synthesis assay.

PAF synthesis assay: PAF synthesis by PMN and monocytes was quantified with a
metabolic labeling approach as previously described (26). Ten million cells (PMN or
monocytes) were incubated in Hanks Balanced Salt Solution (HBSS) with 25 pCi/ ml
[3~]-aceticacid (3.10 Cilmmol, Perkin Elmer, Boston, MA), 25 mglml fatty acid free
Bovine Serum Albumin (BSA) for 10 minutes at 37OC. After 10 minutes of prelabelling
with [3~]-aceticacid, 15 pM calcium ionophore A21 837 (Signial Aldrich, St. Louis, MO)
or vehicle (dimethylsulfoxide, DMSO) was added and the incubation was continued for
an additional 50 min. After the incubation, cells were harvested and washed with HBSS

to remove excess radiolabel. Lipids were extracted with the method of Bligh and Dyer
(27) and separated by TLC using a previously described method (24). PAF was
identified based on co-migration with authentic PAF (Avanti, Alabaster, AL). The PAF
band was scraped from the TLC plate and radio-labeled PAF was quantified by
scintillation counting and normalized to total acetate uptake. This assay measures total
PAF accun~ulationand does not distinguish between alkyl-PAF and acyl-PAF.

Statistical Methods: Normalized PAF synthesis (dpm PAFI dpm acetate incorporated)

was assessed by replicate determinations within each subject under two treatment
conditions, vehicle (DMSO, resting cells) and 15 yM IoA (activated cells). Normalized
PAF synthesis proportions were estimated by the log difference of decays per minute
(dpm) in PAF and total dpm incorporated, yielding a ratio of the geometric means. The
repeated-measures were taken into account by a mixed-model repeated-measures analysis
of variance using the SAS MIXED procedure. The log-difference of the results were then
summarized by back-transforming the results into proportions or ratios for interpretation.

Results:
We hypothesized that increased synthesis would contribute to elevated PAF levels in
LAgP subjects. To address this question, we quantified PAF synthesis by monocytes
and PMN, two cell populations that are known to be atypical in LAgP subjects and are
closely associated with PAF synthesis. Monocytes and PMN were isolated from ageand race-matched subjects who were non-periodontitis (NP) or LAgP patients. The cells
were metabolically labeled with [3~]-acetate,
incubated with vehicle (DMSO) or calcium
Ionophore A23 187 (IoA), lipids were extracted and separated by TLC, and radiolabel
incorporation in PAF (PAF synthesis) was quantified. The metabolic label was readily
incorporated into monocytes and PMN of both subject groups. Although there was
considerable subject to subject variability, mean acetate incorporation was not
statistically different (p > 0.05) between resting nionocytes (Figure 3A) or PMN (Figure
3B) from both subject groups. IoA stimulation did not alter acetate incorporation in either
subject group or cell type (data not shown). To account for subject to subject variability
in acetate uptake, PAF synthesis data are expressed as the ratio of dpm in PAF to dpm
acetate uptake (normalized PAF synthesis) throughout this report.
As shown in Table 2, vehicle-treated (resting) LAgP and NP monocytes synthesized
similar amounts of PAF. Similar results were obtained with monocytes from two
additional subject groups, chronic periodonititis (CP) and generalized aggressive
periodontitis (GAgP) (data not shown). In contrast, PAF synthesis was significantly
higher in resting LAgP PMN than NP PMN (Table 3). The 95% confidence intervals in
Tables 2 and 3 were determined with a model that assumes equal variance in the LAgP
and NP data sets. However, an analysis of the individual determinations suggests

Table 2: PAF Synthesis in Monocytes

Treatment

Subject
Group

N

Mean*
(X 103)

95% CI

-3.3
5

1.6

6.8

LagP
loA
NP

8

2.8

1.6

4.9

5

46.6

21.4

101.5

LagP

8

11.4

6.1

21.5~

Vehicle

NP

Monocytes were isolated from "n" subjects, metabolically labeled with ['HI-acetate, and
then incubated with vehicle (DMSO) or 15 pM calcium ionophore A238 17 (IoA).
Radiolabel incorporation into PAF was quantified and normalized PAF synthesis
calculated as described in Materials and Methods.
*mean normalized PAF synthesis X 10' and 95% confidence intervals (95% CI)
@

Statistically different than NP (p < 0.008)

Table 3: PAF Synthesis in PMN

Treatment

vehicle

loA

Subject
Group

n

Mean*
(X 103)

95% CI

NP

10 0.1

0.1

0.2

LAgP

9

0.3

0.2

0.7~

NP

10 4.6

2.5

8.5

LAgP

9

8.7

40.4~

18.7

PMN were isolated from "n" subjects, metabolically labeled with [3~]-acetate,
and then
incubated with vehicle (DMSO) or 15 pM calcium ionophore A238 17 (IoA). Radiolabel
incorporation into PAF was quantified and normalized PAF synthesis calculated as
described in Materials and Methods.
*mean normalized PAF synthesis X lo3 and 95% confidence intervals (95% CI)
@

Statistically different than NP (p < 0.02)

Figure 3A

h

Y
'
0

20000

-

16000

-

7

X

EP

12000

-

Q,

z

(P
C,

P

8000

-

a

Q,

C,

4000

-

(P
+

Q,

4

0

LAgP

NP

Figure 3A: Acetate Incorporation into Monocytes and PMN. Monocytes and PMN
were isolated from peripheral blood of non-periodontitis (NP) and localized aggressive
periodontitis (LAgP) subjects. The cells were metabolically labeled with 25 pCil ml

[3~]-

acetate for 60 min and an aliquot was harvested and scintillation counting performed to
quantify acetate incorporation into the cells. The data are expressed as mean dpm acetate
incorporated x

Error bars indicate the 95% confidence intervals. The data were

collected from resting leukocytes. Acetate incorporation into IoA-stimulated leukocytes
did not differ from resting cells (p > 0.05, data not shown). A. Acetate incorporation into
NP (n=5) and LAgP (n=8) monocytes.

Figure 3B

Figure 3B: Acetate Incorporation into Monocytes and PMN. Acetate incorporation
into NP (n=10) and LAgP (n=9) PMN. Acetate incorporation did not differ between
LAgP and NP leukocytes (p > 0.05).

that variance within the LAgP monocyte data set is considerably larger than that of the
NP data set (Figure 4, p < 0.03). The resting LAgP and NP PMN data sets exhibited
similar degrees of variance (data not shown).
Activated leukocytes are major sources of PAF (13-15). PAF production is induced
by proinflammatory molecules like LPS (28,29) and MCP-I and we initially used these
as stimuli for PAF synthesis. However, subject-to-subject variation in the responses to
these stimuli often exceeded differences between the diagnostic groups (data not shown),
possibly due to differences in expression of the receptors for these stimuli. Therefore, we
chose a more potent, receptor-independent stimulus, calcium ionophore (IoA) (26,30,15)
to compare PAF synthesis in activated LAgP and NP leukocytes. As expected, IoAstimulation increased PAF synthesis by leukocytes from both LAgP and NP subjects with
robust responses observed in both populations. Like resting LAgP PMN, IoA-activated
LAgP PMN synthesized more PAF than did NP PMN (Table 3, p < 0.02). Unexpectedly,
LAgP monocytes made a very modest response to IoA (Table 2) such that PAF synthesis
in this group was -4-fold lower than in IoA-activated NP monocytes. These data
indicated that LAgP monocytes synthesized less PAF than did activated NP monocytes.
To more directly assess the responses of LAgP monocytes to IoA, we expressed the data
as fold induction of PAF synthesis in response to IoA (Figure 5A) and also quantified the
responses of monocytes from GAgP and CP subjects. Similar amounts of PAF were
produced by resting monocytes from all four subject groups (reported in figure legend).
When stimulated with IoA, NP, CP, and GAgP monocytes made similar responses, as
IoA induced PAF synthesis by -12-fold. In contrast, LAgP made a more modest -4-fold
response to IoA (p < 0.001). Fold induction of PAF synthesis in PMN is shown in Figure

5B. Resting NP, CP, and GAgP PMN synthesized similar amounts of PAF (data not
shown, p > 0.05) but resting LAgP PMN synthesized more PAF than did NP PMN (Table
3) but not GAgP or CP PMN (data not shown, p > 0.05). Although the absolute amount
of PAF synthesized by LAgP PMN was higher than that of NP PMN (Table 3), the
relative response to IoA (fold induction) was similar in all four groups PMN (Figure 5B,
p > 0.05). Together, these data suggest that LAgP monocytes have a unique phenotype
with respect to calcium signaling that may impact on PAF synthesis in activated cells.
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Figure 4: Variance in PAF Synthesis in Resting Monocytes.
Lipids were extracted from metabolically labeled resting NP (n=5) and LAgP (n=8)
monocytes. PAF was separated from other lipids by TLC, the PAF spots were identified
and scraped from the TLC plates, and radiolabel incorporation was quantified by
scintillation counting. Shown are individual data for each monocyte preparation studied
expressed as the mean normalized PAF synthesis X 103. Normalized PAF synthesis is
the ratio of dpm in PAF to total dpm [3~]-acetate
incorporated into the cells. *, Variance
within the population of LAgP subjects was significantly different from the NP
population (p = 0.003).

Figure 5A: LAgP Monocytes Make Modest PAF Responses to IoA. Metabolically
labeled monocytes from NP (n=5), LAgP (n= 8), GAgP (n= 5), and CP (n=5) subjects
were stimulated with 15 yM ionophore A23 187 (IoA). Lipids were extracted, radiolabel
incorporation into PAF was quantified, and normalized PAF synthesis was calculated as
described in the legend of Figure 3. The data are expressed as fold induction of PAF
synthesis in response to IoA, calculated as the ratio of normalized PAF synthesis in IoAtreated cells to normalized PAF synthesis vehicle-treated cells. The mean and 95%
confidence intervals (error bars) are shown. A: Fold induction of PAF synthesis in IoAstimulated monocytes. Normalized PAF production by resting monocytes (mean (95%
confidence intervals)) X lo3: NP, 3.3 (1.6, 6.8); LAgP, 2.8 (1.6,4.9); GAgP, 2.0 (1.0,
4.1); CP, 3.6 (1.7,7.4).

*, the IoA responses of NP, CP, and GAgP monocytes were more

robust than those of LAgP monocytes (p= 0.0001). B: Fold induction of PAF synthesis
in IoA-stimulated PMN. Normalized PAF synthesis by resting PMN (mean (95%
confidence intervals) X lo3: NP: 0.08 (0.05,O. 16); LAgP 0.32 (0.15, 0.71); GAgP, 0.22
(0.09,0.53); CP 0.18 (0.06,0.54). The IoA responses of NP, CP, GAgP, and LAgP PMN
were not significantly different (p > 0.05).
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Discussion:
Other investigators have demonstrated that PAF levels are higher in the tissues of
LAgP than NP subjects (17-21). Our data support the hypothesis that PAF accumulation
in LAgP can be attributed to alterations in both its catabolism and its synthesis, and that
monocytes and PMN contribute differently to total PAF levels. In a previous study (24),
we reported that the activity of the catabolic phospholipase PAF acetylhydrolase
(PAFAH) is lower in LAgP monocytes than in NP monocytes. As monocytes are the
major source of PAFAH (29), these data suggest that the unique phenotype of LAgP
monocytes contributes to PAF levels through reduced catabolism. In the current study,
we demonstrate that resting and activated LAgP PMN synthesize more PAF than do NP
PMN (Table 3). This observation indicates that PMN may contribute to the high levels of
PAF in LAgP subjects' tissues through increased anabolism. Thus, synthesis and
degradation are likely to play important roles in PAF accumulation in the tissues of LAgP
subjects, and monocytes and PMN differ in their contributions to PAF accun~ulation.
In resting monocytes, normalized PAF synthesis was similar in the LAgP and NP
subject groups (Table 2). However, there was significantly greater variance in PAF
synthesis in the LAgP subject group than in the NP subject group (Figure 4). At present,
we are not certain why the LAgP subject group exhibited greater variance. PAF is a
proinflammatory lipid mediator that is produced when monocytes encounter microbial
pathogens (16,30). Thus, the high levels of PAF synthesis by some LAgP subjects'
monocytes could be episodic and a consequence of exacerbated disease. Additional
experiments are necessary to test this hypothesis.

Resting LAgP PMN synthesized more PAF than did NP PMN (Table 3), suggesting
that PMN contribute to the high levels PAF observed in LAgP subjects through and NP
that anabolism. The calcium ionophore A23 187 (IoA) has previously been shown to
induce PAF (15,26,28) and was used to compare PAF synthesis in activated NP and
LAgP leukocytes. Although IoA induced PAF synthesis in both monocytes and PMN
from both LAgP and NP subjects, the degree of response varied between the groups.
While IoA stimulated PAF synthesis by more than 10-fold in NP monocytes, LAgP
monocytes made a more modest -4-fold response (Table 2, Figure 5A). This observation
is reminiscent of previous reports of aberrant calcium responses in LAgP PMN that have
been correlated with defective chemotaxis, reduced protein kinase C activation, and
reduced activity of a calcium influx factor (3 1-34). Thus, aberrant calcium signaling may
be a hallmark of LAgP monocytes as well. The IoA responses of two additional subject
groups, generalized aggressive periodontitis (GAgP) and chronic periodontitis (CP), were
similar to those of NP monocytes (Figure 5A). These observations highlight the unique
phenotype of the LAgP monocyte with respect to lipid metabolism and calcium signaling.
The modest response of LAgP monocytes to calcium ionophore was somewhat
unexpected as these cells are known to be hyperresponsive to at least one other stimulus,
LPS (37,38). As calcium is not involved in LPS signaling, these observations support the
hypothesis that LAgP monocytes may have selective alterations in calcium signaling and
not more general defects in signal transduction. At present, the specific mechanisms for
blunted IoA responses in LAgP monocytes are uncertain. Nevertheless, it is of interest
that calcium signaling appears intact in monocytes from subjects with GAgP, a closely
related disorder. LAgP and GAgP tend to appear in the same families and are sometimes

classified as alternate forms of the same disease (39). However, there is precedence for
differential immune responses in LAgP and GAgP subjects. For example, although LPS
triggers the same robust IL- 1 responses in LAgP and GAgP monocytes, the LAgP cells
produce considerably more PGE2 and TNFa than do GAgP monocytes (37). Furthermore,
while smoking suppresses circulating IgG2 antibodies in NP and GAgP subjects, IgG2
levels are not affected in LAgP subjects who smoke (4.0). Together, these data underscore
the unique biology of LAgP and suggest that this disease may be separate and distinct
from GAgP.
Previous reports indicate that LAgP PMN also manifest aberrant calcium responses
(10, 3 1-34). Consistent with this, IoA-stimulated LAgP PMN produced more PAF than
did IoA-stimulated NP PMN (Table 2). However, the fold induction of PAF synthesis in
IoA-stimulated LAgP PMN was similar to that of NP, CP, and GAgP PMN (Figure 5B).
These observations suggest that the aberrant calcium responses of LAgP PMN do not
hinder IoA-induced PAF synthesis. The response to IoA, a non-physiological stimulus
that induces exceptionally large increments in cytosolic calcium, may be so robust that it
masks the more modest alterations in the calcium responses of LAgP PMN.
Alternatively, the IoA stin~ulusmay compensate for defects in the calcium signaling of
LAgP PMN. Previous reports indicate that stimulus-dependent release of calcium from

ER stores is intact in LAgP PMN but that the entry of extracellular calcium andl or
redistribution of intracellular calcium are aberrant (10,32). As a result, fMLP- and IL8stimulated LAgP PMN exhibit more robust increases in cytosolic calcium than do control
PMN (10). It is possible that the same is true for IoA-activated LAgP PMN and that this
results in increased PAF synthesis. Further experiments are needed to delineate the

differences in intracellular calcium stores and calcium signaling in LAgP PMN and
monocytes.
Our studies add to a growing body of evidence that LAgP leukocytes exhibit an
unusual lipid metabolism that impacts on their ability to mount responses against oral
pathogens. Diacylglycerol (DAG) accumulates in LAgP PMN due to reduced activity and
expression of diacylglycerol kinase-a (DGKa) (35,36). It has recently been suggested
that the accumulation of DAG may render LAgP PMN "hyperf~~nctional"
and thereby
exacerbate inflammatory responses associated with the disease (37). LAgP PMN are
known to synthesize large amounts of leukotriene B4 (LTB4) and lipoxin & (LX&),
bioactive lipids that have pro- and anti-inflammatory activities, respectively (36,37).
Prostaglandin E2 (PGE2) levels are high in LAgP and have been suggested as a measure
of disease severity (38-40). LAgP monocytes are implicated as the source of this
bioactive lipid (41) which is associated both with exacerbation of disease and the
induction of protective IgG2 antibodies that lessen disease severity (23,42). The biology
of PAF is quite similar as it promotes both inflammation and IgG2 antibodies (16,22,
23). Our next challenge is to distinguish the molecular mechanisms and intracellular
signaling pathways associated with the protective versus the pro-inflammatory responses
of these bioactive lipids. Increased understanding of lipid metabolism and signaling in
LAgP n~yeloidcells may allow us to harness this unique cell biology to devise strategies
to control the disease.

Chapter 3: CD36 Expression and Uptake of AcLDL in LAgP and NP Monocytes
Introduction:
In addition to modulating the immune system, monocytes also impact inflammatory
processes within the body. Recently, evidence has been accumulating linking
periodontitis to the pathogenesis of atherosclerosis. This has coincided with a shift in
thinking of periodontal disease as an inflammatory disease capable of influencing
systemic health rather than as a local process limited to the oral cavity. New data
supports an association between atherosclerosis and alveolar bone loss, indicating that
prolonged infection might be related to the buildup of atherosclerotic plaque (92). A
meta-analysis of both prospective and retrospective studies demonstrates a 20% increased
risk (95% confidence interval (CI) 1.08-1.32) of cardiovascular disease (CVD) (93).
There is an even greater risk of stroke with periodontal disease that varies from 2.85 (CI
1.78-4.56) to 1.74 (CI 1.08-2.8 1) (93). Overall, evidence supports an association if not a
casual relationship between periodontitis and an increased risk for CVD.
In terms of early atherogenic events leading to CVD, the formation of foam cells is
thought to be a critical initial event in the formation of new lesions. The microarray data
performed on LAgP subjects also indicated differential gene expression for a key
scavenger receptor thought to play a central role in foam cell formation, the CD36
receptor (75). CD36 is a type B scavenger receptor and a member of the receptor family,
which includes SR-B 11CLA-1, and the HDL (high density lipoprotein) receptor (75).
These scavenger receptors are cellular receptors that bind and internalize modified LDL
particles (including OxLDL) and are found in all mammalian species.

Figure 6: CD36 is a Scavenger Receptor for OxLDL from Nicholson et al. (45).

Nicholson et al. describe a model in which CD36 uptake of oxidized LDL plays a central
role in foam cell formation wi.thin the intimal layer of the vessel wall. In this model,
circulating monocytes are attracted to sites of injury by chemotactic stimuli, diapedese
through the endothelial cell layer into the intima, where they can differentiate into
macrophages. .As macrophages wi.th increased CD36 expression, they can take up LDL
which is also modified within the intima by reactive oxygen species generated at the site
by PMN to form oxidized LDL. The oxidized LDL is thought to bind CD36,
internalized, then accun~ulatewithin macrophages to fornl foam cells (45).

In recent years the literature has supported a model of atherosclerotic disease as an
inflammatory disorder iilvolving macrophages and scavenger receptors (75). Figure 6 is
an illustration taken from a review by Nicholson et a1 describing the role of CD36 as a
scavenger receptor for oxidized LDL (oxLDL) and how binding of oxLDL results in
foam cells within the intimal layer of the vessel wall (45). Initially, monocytes are
attracted to inflammatory sites by chemokines, and chemotax to these areas, then
diapedese through the endothelium to reach the intimal layer. Within the intima, two key
events, chemical modification of LDL and monocyte maturation of macrophages, occur
to promote the initial inflammatory response (45). Reactive oxygen species released in
the intima modify LDL to the oxidized forms (45). Oxidized LDL is then taken up by
CD36 and other scavenger receptors expressed on macrophage surfaces (45). Continued
uptake of oxLDL results in cholesterol ester accumulation within these cells, which is
thought to lead to the formation of foam cells (45).
Evidence to support the role of CD36 in the development of atherosclerosis comes
from experiments done by Febbraio et a1 with a CD36 null mouse (78). Febbraio et a1
observed significantly reduced binding and uptake of OxLDL in peritoneal macrophages
of null mice compared to control (78). Their findings were also supported by previous
work done by Kashiwagi et a1 describing a genetic polymorphism in the CD36 gene in
an Asian population (76). Subjects with this polymorphism were found to be deficient in
the expression of CD36 (NAK "- phenotype) (76). Monocyte derived macrophages
isolated from these NAK

phenotype patients were observed to bind 40% less oxLDL

"'

and to accumulate 40% less cholesterol ester (CE) than normal controls (77). Additional
data comes from experiments Febbraio et a1 in which CD36 null mice crossed with apoE

null mice to generate a CD36-apoE double-knockout mouse (78). These mice were
maintained on high fat diet and were still found to have 70% fewer aortic lesions as
determined by en face analysis of the aortic tree (79). This murine model of
atherosclerosis developed by Febbraio et a1 and the NAKa-phenotype support the
hypothesis that CD36 is a major receptor for proatherogenic lipids and promotes the
formation of atherogenic lesions.
CD36 is expressed by monocytes/macrophages, platelets, microvascular endothelial
cells, dendritic cells, and adipose tissue (80). Ligands for CD36 include OxLDL, anionic
pliospholipids, apoptotic cells, thrombospondin (TSP), collagen, plasmodium falciparuminfected erythrocytes, long-chain fatty acids, HDL, and LDL modified by monocyte
generated reactive nitrogen species (80). Expression of CD36 in monocytes and
macrophages depends on both the differentiation state as well as exposure to soluble
mediators (80). Induction of CD36 mRNA also results in increased CD36 protein, with
the greatest induction (fourfold) by OxLDL(80). In addition, induction of CD36 by
OxLDL is due to activation of the transcription factor PPAR-y (peroxisome proliferators
activated receptor- y).
PPAR-y is a member of the nuclear hormone receptor superfamily and can
heterodimerize with the retinoid X receptor (RXR). PPAR-y and RXR are transcriptional
regulators of genes encoding proteins involved in adipogenesis and lipid metabolism.
Other PPAR-y ligands (such as 15-deoxy-12,14-prostaglandin J2, and the
thiazolidinedione class of anti-diabetic drugs) are known to increase CD36 expression
(90). In an assay developed by Nagy et all in 1998, OxLDL was shown to increase
reporter activity in cells transfected with a PPAR-y response element containing reporter

gene (91). The components of oxLDL involved in the activation of PPAR-y were
identified as two oxidized metabolites of linoleic acid: 9-hydroxyoctadecadienoic acid
(9-HODE) and 13-HODE (91). Both oxidized metabolites were potent activators of
PPAR-y activity (91). In contrast, neither LDL, cholesterol, nor oxidized metabolites of
cholesterol induced transcriptional activity in this assay (91). These results suggest that
macrophage expression and foam cell formation is regulated by PPAR- y activation
secondary to the binding and internalization of oxidized lipids by scavenger receptors.
Foam cell formation may be a result of continued CD36 expression in a positive feedback
loop in which lipids are able to drive the continued expression of their own lipoprotein
receptor.
In addition to their central role in.atherosclerosis through the uptake of modified LDL,
scavenger receptors also play a role in immunosurveillance. Scavenger receptors may
serve as an important host defense mechanism against increased inflammation. This
illustrates a mechanism for lipid regulation of the innate immune and host inflammatory
response through the sensing of inflammatory "danger signals" by sentinel immature
dendritic cells expressing CD36. Brown and Goldstein noted: "The scavenger receptor
might compete with collagen for binding of oxidized LDL and perhaps other toxic
molecules. Macrophages might glide along collagen fibrils, using their scavenger-cell
receptors as vacuum cleaners to suck up oxidized lipoproteins and other polyanions that
are stuck to collagen." (73). The receptor CD36 enables scavenger cells, such as
macrophages, to ingest and degrade oxidized and chemically altered proteins. This would
explain its occurrence in wandering macrophages, which can invade poorly perfused
tissues that might become depleted of antioxidants and prone to generate reactive oxygen

species. It might also explain the receptor's unusual abundance in the endothelium of
hepatic sinusoids, where scavenger receptors may function as filters to remove oxidized
proteins from the bloodstream, whereas on phagocytic cells sucl~as macrophages, CD36
plays a role in promoting immunosurveillance and modulating the inflammatory
response.
Based on our microarray data, we predicted differential gene regulation of CD36 in
LAgP population with increased CD36 expression in LAgP monocytes compared to NP
control. This seemed consistent with previous reports of a connection between
periodontitis and atherogenesis and atherosclerotic disease. In addition, given the fact
that atherosclerosis is initially due to inflammation, this would lead us to predict
increased scavenger receptor expression and function in a population such as LAgP with
underlying chronic inflammation.

Methods and Materials:
Human Subjects: Human Subjects as described previously were used in this study. 60
ml peripheral blood was obtained from each subject and monocytes were isolated as
described below.

Cell Isolation and Culture: Monocytes were isolated as described previously using
Ficoll gradient. loA7cells were plated into each well of a plastic 6 well culture dish and
allowed to adhere to the plastic culture plates for 1 hour in RPMI media at 37 degrees C
and 5% C02. At the end of the 1 hr incubation, non-adherent cells were washed off twice
with RPMI. Cells were then cultured in RPMI containing PCNIStreptomycin and
Glutamate and 10% Hunian AB serum, and differentiated for 4 days into dendritic cells
andlor macrophages. Cells were kept in the incubator at 37 degrees Celsius, 5 %
humidity, and 5% C02. After 4 days in culture, the adherent cells were exposed to 2.5
mM EDTA and 5% Human AB serum in RPMI for 20 minutes, then placed on ice and
gently scraped using a rubber policeman to lift the cells off the culture plate surface. The
cells were then pelleted by centrifugation at 1000 x g for 5 minutes at 4 degrees Celsius,
washed twice with sterile PBS, and then used for FACS analysis and AcLDL (Acetylated
LDL) experiments.

Flow Cytometry: Adherent monocytes cultured for 4 days in RPMI and
PenicillinlStreptomycin containing Glutamate and 10% Human AB Serum were analyzed
for expression of CD36 cell surface receptor and uptake of FITC-conjugated AcLDL
(Molecular Probes, Invitrogen, Eugene, OR). Adherent cells from each well of a 6 well

culture plate were incubated with a blocking antibody for 10 minutes on ice, followed by
incubation with either 20 ml of FITC-conjugated CD36 or PE-conjugated CD1 lc, both
FITC-CD36 and PE-CDl lc, or the appropriate isotype control for 30 minutes on ice, and
washed twice with PBS. CD36, CDl lc, and isotype-matched controls were obtained
from BD Pharmigen, San Diego, CA. Labeled cells were then resuspended in 400 ml of
PBS containing 0.1 BSA and run on a Cytomics FC500 Flow Cytometer Instrument using
the CXP software.
Fluorescently coupled antibodies and isotype controls were purchased from either BD
Pharmigen or Immunotech, a Beckrnan Coulter company. CD36-FITC (FA6.152) also
unlabeled CD36 (FA6.152) not conjugated to FITC were purchased from Immunotech, a
Beckman Coulter Company (Marseille, France). IgG1-FITC was purchased from
Immunotech, a Beckman Coulter Company (Marseille, France). Data were expressed as
MFI and % of cells displaying staining. Cells labeled with isotype-matched controls
demonstrated less than 2% staining and MFI less than 3.

Quantitative RT-PCR: Quantitative RT-PCR was performed on RNA isolated as

described previously. RNA was extracted from both freshly adherent monocytes and
monocytes that had been cultured in RPMI and 10% HS containing PIS and Glutamate.
Quantitative real-time PCR was performed using a BioRad Icycler real time PCR
machine available in the Clinical Research Center for Periodontal Diseases. Primers and
Taqman probes were either obtained from sequences published in the literature or
designed using the "Beacon Designer" software from BioRad and obtained from IDT
(Integrated DNA Technologies, Coralville, IA). 18s ribosomal RNA was used as our

internal control and all data was normalized to the internal housekeeping control 18s.
18s sense: 5' - AAA ATT AGA GTG TTC AAA GCA GGC -3'.
18s antisense: 5'- CCT CAG TTC CGA AAA CCA ACA A -3'.
The 18s probe was labeled with Cy5-635.
18s probe: 5' - 15Cy51CGA GCC GCC TGG ATA CCG CAG C 13BHQ-21-3'.
Sequences for the primers and probes were as follows:
CD36 sense primer: 5'-TGG GAA AGT CAC TGC GAC AT -3'.
CD36 anti-sense primer: 5'- TGC AAT ACC TGG CTT TTC TCA -3'.
CD36 probe:
5'- 156-FAMIATT AAT GGT ACA GAT GCA GCC TCA TTT CCA C-3BHQ-1-3'
Standard curves were run and only runs generating a standard curve with an correlation
coefficient greater than 0.99 and a PCR efficiency greater than 90% were used for data
analysis. The protocol for 18s was 48 degrees C for 30 minutes, followed by 95.0
degrees C for 9 minutes, followed by 40 cycles of 95 degrees C for 15 seconds followed
by 60 degrees for 1 minute, with a hold at 4 degrees C at the end of the 40 cycles.

Aceylated LDL Uptake Experiments: FITC-AcLDL was obtained from Molecular
Probes, a division of Invitrogen (Eugene, OR). Adherent monocytes were incubated with
10 pg of FITC-AcLDL (Immunotech) and incubated in a 37 degrees C water bath for
time points of lh, 2h, 4h and 6h to determine optimal time for incubation. In addition,
dose response experiments were performed with monocytes incubated with 5 pg, 10 pg,
and 20 pg FITC-AcLDL. The CD36 blocking antibody, FA6.152 was obtained from
Immunotech, Beckman Coulter (Marseilles, France). Labeled cells were washed twice in

PBS to remove non-specific binding and unbound antibody. Cells were then incubated in
PBS containing 0.5% BSA and run on the Flow Cytometer. CD36 was determined at the
same time and same settings used for CD36 analysis were used to determine the MFI and
the percentage of cells that bind and uptake FITC-AcLDL.

Results:
There has been increasing evidence in the literature supporting a link between
periodontitis, a chronic inflammatory disorder and atherosclerosis. Table 4 illustrates
differential gene expression of CD36, the key scavenger receptor thought to play a role in
initial foam cell formation. With an n of 5, and a standard error of 9.1, the microarray
results suggests a 10.8 fold higher level of expression in LAgP monocytes compared to
NP control.
To verify the microarray data, CD36 gene expression was analyzed using the more
quantitative approach of real-time RT-PCR. RNA was extracted from freshly isolated
PBL monocytes and used for quantitative RT-PCR to measure CD36 gene expression.
All data were normalized back to 18s. There was no statistically significant difference in
CD36 gene expression in freshly isolated LAgP monocytes compared to NP control (data
not shown). However, CD36 gene expression in our adherent LAgP monocytes cultured
for 4 days in RPMI and 10% Human AB serum was significantly increased compared to
that of similarly treated NP controls, with a p = 0.01 (Figure 7). There was nearly a 4
fold increase in the mean value normalized CD36 expression for LAgP group compared
to NP control. Despite some overlap at the lower levels of expression, none of the NP
subjects had expression levels at the higher end of the spectrum.
Next, we examined protein expression of CD36 using FACS analysis. Freshly
isolated PBL monocytes stained with anti-CD36 and anti-CDl lc. Double positive cells
were gated and analyzed for MFI (mean fluorescent intensity) and percentage of cells
expressing the CD36 scavenger receptor. Background and nonspecific binding were
controlled for using a isotype matched control with less than 2% cells with staining and

Table 4: CD36 Microarray Data
Accession #

Gene

Fold Change

SE

n

NM-006820.1

CD36

10.8

9.1

5

Monocytes were isolated from LAgP and NP controls and result was obtained when each
NP subject was compared to each LAgP subject. Microarray data showing 10.8 fold
increase in CD36 gene expression in LAgP monocytes compared to age and race matched
NP monocytes, with a standard error of 9.1, and an n of 5 subjects. Accession number is
also shown.

an MFI less than 3. Figure 8 shows a nearly statistically significant difference in protein
expression of CD36 in freshly isolated LAgP monocytes compared to NP control. These
results did not agree with the microarray data, and were not verified by our quantitative
RT-PCR experiments.
Given the striking results of the quantitative RT-PCR experiment on monocytes cultures
for 4 days and allowed to differentiate in to dendritic cells or macrophages, we
concentrated our next set of experiments on these differentiated monocytes. With both
microarray and quantitative RT-PCR suggesting increased CD36 expression in our LAgP
monocytes, we next tried to quantity the level of protein expression at the cell surface.
Monocytes were cultured for 4-5 days and allowed to differentiate, then adherent cells
were analyzed for CD36 expression using Flow Cytometry. There was no difference in
the percentage of cells positive for CD36 or the MFI for CD36 expression between LAgP
and NP control monocytes.
We also examined LAgP and NP monocytes for differences in ability to take up
cliemically modified LDL. Monocytes were cultured for 4-5 days as previously
described, then incubated with aceylated LDL (AcLDL) conjugated to the fluorescent dye
FITC. Binding and uptake of the AcLDL was measured by flow cytometry. Figure 9
shows the results of both a time course and dose response experiment for the uptake of
FITC-AcLDL. In figure 9A, there was no predictable trend in the percentage of cells that
take up AcLDL as incubation time increased (Figure 9A). MFI was greatest at the 6h
incubation, and with the exception of the 4 hour time point, there was a time dependent
increase in MFI (Figure 9A). Figure 9B shows the results of incubating monocytes with
increasing amount of AcLDL.

Again, there was no predictable trend in percentage of

cells that take up AcLDL with increasing doses. There was a dose dependent increase in
MFI with maximal MFI observed at 20 pg, but only slightly higher than the MFI
observed at 10 pg. Based on these findings, subsequent experiments for AcLDL uptake
were carried out at a dose of 10 pg for and a 6 h incubation.

Figure 7: Comparison of CD36 Gene Expression in LAgP and NP Monocytes

LAgP

NP

* significantly lower than LAgP expression, p=0.01

Monocytes were isolated from the peripheral blood of LAgP and NP subjects and
cultured for 4-5 days. RNA was extracted and quantitative RT-PCR was used to
determine CD36 gene expression. CD36 mRNA expression was normalized to 18s
ribosomal RNA expression. Samples were run in duplicate and sometimes in triplicate.
Mean values for RNA expression for LAgP was 1108 +I- 940 and 244 +I- 276 NP
monocytes. The NP group had statistically significantly lower CD36 mRNA expression
compared to LAgP group, p = 0.01.

Figure 8: Comparison of CD36 Surface Receptor Expression Using Flow Cytometry
CD36 Expression in LAgP and NP Monocytes

--

Monocytes from 9 LAgP and 8NP subjects were isolated over a Ficoll gradient, then
analyzed for CD36 receptor expression using flow cytometry. 1 0 " ~cells were stained
with 20 p1 FITC-CD36 andlor PE- CDl lc. Monocytes were identified as cells
expressing CD 11c. Population of interest was identified as CD 11c+CD36+, and the MFI
and percentage of cells staining for CD36 within this double positive population was
analyzed. CD36 MFI in LAgP monoctyes was not quite statistically significant
compared to NP, p= 0.506. There was no statistically significant difference in the % cells
positive for CD1 l c and CD36. Mean CD36 MFI for NP monocytes was 54.7 with a
standard deviation of 39.1; and the mean CD36 MFI for LAgP monocytes was 19.0 with
a standard deviation of 19.

Figure 9A: Results of time course for AcLDL uptake by nionocytes isolated from
peripheral blood of JP 3807. Monocytes were isolated and plated on 6 well culture plates
for 4-5 days in RPMI and 10% human serum. Cells were allowed to differentiate and
adherent cells were isolated as described in Materials and Methods. Cells from each well
were incubated with 10 pg of FITC-conjugated AcLDL for various time points (lh, 2h,
411, and 6h) at 37 degrees C in a shaking water bath and light protected. At the end of the
incubation, excess unbound FITC-AcLDL was washed off, and cells were analyzed for
amount AcLDL binding and uptake using Flow Cytometry. The top bar graph shows the
percentage of cells that take up AcLDL and graph below indicates the MFI of FITCAcLDL taken up by these cells. There was no predictable time dependent trend in
percentage of cells that took up AcLDL. MFI was highest at the 6h incubation point.

Figure 9B: Dose Response for FITC-AcLDL uptake by monocytes isolated from LAgP
subject 406. Monocytes were isolated from peripheral blood and cultured for 4-5 days in
RPMI containing human serum as described above. Adherent nionoctyes from each well
were then incubated with increasing doses of 5 yg, 10 yg and 20 yg of FITC-AcLDL for
l h in the shaking waterbath at 37 degrees C. The MFI and % of cells that take up FITCAcLDL were analyzed using Flow Cytometry. The top bar graph in this figure indicates
the percentage of cells and the lower bar graph indicates the MFI of FITC-AcLDL taken
up by the monocytes. There was no dose-dependent trend in the percentage of cells that
took up AcLDL. MFI increased in a dose-dependent manner with a maximal MFI at 20
Clg.

Figure 9A: Time course for AcLDL Uptake by Adherent Monocytes Cultured 4d in
Human Serum
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Figure 9B: Dose Response for AcLDL Uptake by Adherent Monocytes Cultured 4d
in Human Serum
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The next set of experiments was to determine specificity and involvement of CD36 in
the uptake of AcLDL by these differentiated monocytes. To determine whether or not
AcLDL uptake involved the CD36 receptor, we incubated cells with unlabeled antibody
to anti-CD36 (FA6.152). Results from different experiments have shown conflicting
results, but in this experiment with a 10 pg dose of FITC-AcLDL, incubation with the
blocking antibody causes a significant reduction in both the MFI and percentage of cells
that bind and uptake AcLDL (Figure 10). This decrease in MFI was repeated in another
experiment with an NP subject (Figure 1I). However, in the NP subject, no decrease in
the percentage of cells capable of binding and taking up FITC-AcLDL was seen, however
a significant decrease in MFI was observed (Figure 11).
These initial experiments lead us to believe the differences in LAgP expression of
CD36 and increased uptake of AcLDL may be due to differences in dendritic cells versus
macrophages. When monocytes that had cultured in RPMI and 10% human serum were
analyzed for CD36 expression, it was noted that within each well, cells floating in the
media had significantly less CD36 expression compared to the adherent cells of that same
well. This result was reproducible and figure 12 demonstrates the results of a
representative experiment. This seemed to support the hypothesis that dendritic cell
biology was important. To corroborate this hypothesis, monocytes isolated from a buffy
coat sample obtained from the Virginia Blood Services were adhered to a plastic culture
plate and differentiated into dendritic cells or macrophages using cytokines GM-CSF plus
IL-4 and M-CSF, respectively. After culture for 7 days, the adherent cells were isolated,
stained with anti-CD36 to examine differences in protein expression, and incubated with
FITC-AcLDL to examine differences in AcLDL binding and uptake capacity.

Compared to the monocyte-derived dendritic cells, the macrophages exhibit significant
decreases in both MFI and percentage of cells that take up AcLDL (Figure 13).

Figure 10: Decreases in Percentage of Cells that Uptake AcLDL and MFI with antiCD36 Blocking Antibody
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Monocytes isolated from the peripheral blood of subject LAgP 3807 were cultured for 4
days in RPMI containing human serum as described in Materials and Methods. Adherent
cells were allowed to differentiate and at the end of 4 days, only the adherent cells from
each well were incubated with 20 pl of unlabeled blocking anti-CD36 antibody
(FA6.152) for l h incubation, followed by 1h incubation with 10 pg FITC-AcLDL.
Decrease in FITC-AcLDL MFI (pink bars) and % of cells that bind and take up FITCAcLDL (green bars) are shown above. Both the MFI and the percentage of cells that
bind and take up FITC-AcLDL are decreased compared to cells incubated with only
FITC-AcLDL

Figure 11: Effect of Anti-CD36 blocking Antibody on CD36 Uptake in NP 7084
Monocytes Cultured 4 d in Human Serum:
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Monocytes from NP 7084 were isolated and cultured in RPMI containing human serum
as described in Materials and Methods and the previous figure. Adherent cells were
treated with 10 mg FITC-AcLDL or preincubated for 1 hr with 20 p1 unlabeled antiCD36 blocking antibody and then treated with FITC AcLDL for 6h. Cells were then
analyzed by Flow Cytometry for MFI and percentage of cells that bind and take up FITCAcLDL. FA6 pretreatment decreased the MFI significantly, but not the percentage of
cells that bind and take up FITC-AcLDL.

Figure 12: CD36 Expression in Floating cells compared to Adherent Cells
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Monocytes from LAgP 5297 were isolated from peripheral blood and cultured 4 days in
RPMI containing 10% human AB serum as described in Materials and Methods.
Adherent nionocytes and cells floating in the culture media were then isolated and
incubated with FITC-labeled anti-CD36. The CD36 expression in these cell populations
was analyzed by flow cytometry. MFI (shaded bars) and percentage of cells staining
positive (clear bars) were quantified for both cell populations and is expressed in the
graph. Adherent cells expressed increased CD36 MFI and percentage of cells positive for
CD36 compared to cells floating in the cultured media. Isotype matched controls were
run and showed less than 1 percent cells with positive staining and an MFI less than 3.

Figure 13: AcLDL Uptake by Monocytes Differentiatied into Macrophages and
Dendritic Cells

OO
/

35

Cells that Uptake AcLDL

MFI

1

+ Anti-PC
GMCSF + IL-4

AcLDL

AcLDL

+ Anti-PC

MCSF

Monocytes isolated from a buffy coat sample were cultured and differentiated using
cytokines. After allowing cells to differentiate for 7 days, adherent cells from each well
were incubated with FITC-AcLDL 5 pg and 2 pg anti-PC (anti-phosphatidylcholine).
MFI and percentage of binding and uptake of FITC-AcLDL was quantified using flow
cytometry. Samples were run in duplicate. Both MFI and binding and uptake of FITCAcLDL were greater in the monocyte derived dendritic cell population.

Discussion:
The microarray results suggest increased CD36 expression in LAgP compared to NP
control monocytes. Increased scavenger receptor expression suggested a mechanism for
such a causal relationship between LAgP and atherosclerosis. The semi-quanitative
microarray data suggesting increased CD36 gene expression was verified by quantitative
RT-PCR only in monocytes cultured for 4 days and allowed to differentiate into dendritic
cells or macrophages. In contrast, neither freshly isolated PBL monocytes nor MACSisolated monocytes demonstrated a statistically significant difference in CD36 gene
expression by quantitative RT-PCR. The culture conditions allowed adherent monocytes
to differentiate into cells exhibiting macrophage or dendritic cell-like morphology.
Results reported by Barbour et a1 described an increased propensity by LAgP monocytes
to differentiate dendritic cells, whereas as NP monocytes demonstrate an increased
propensity to differentiate into macrophages (12). Together the previous findings by
Barbour with the current data suggested that differences in LAgP and NP monocytes
would be more apparent following a 4d culture period in human serum. Under those
conditions, the monocytes would differentiate and allow us to see differences between
LAgP and NP monocytes, especially those closely related to dendritic cell biology.
The differences in CD36 gene expression in differentiated LAgP monocytes and
AcLDL uptake in these pilot experiments suggest gene expression of CD36 may be due
to differences in cell biology. Studies have documented differences in CD36 receptor
expression based on maturation stage, with macrophages expressing increased levels of
this scavenger receptor compared to undifferentiated monocytes (80). It is also possible
that immature dendritic cells have increased CD36 expression compared to mature

dendritic cells. This would explain why adherent dendritic cells, rather than mature
dendritic cells floating in the culture medium have noticeably higher expression of CD36,
both in terms of percentage of cells staining positive, and MFI. However, no studies to
date have compared expression of CD36 in dendritic cells and macrophages. When we
differentiated monocytes from a buffy coat sample, the monocyte derived dendritic cells
exhibited increased ability to bind and take up AcLDL compared to the monocyte derived
macrophages. This suggests that dendritic cells have increased CD36 andlor other
scavenger receptor activity compared to macrophages. This supports the idea that LAgP
subjects would have increased CD36 expression compared to NP monocytes due to their
propensity to develop into dendritic cells and supports the result from the initial
microarray. The increase in percentage of monocyte derived dendritic cells that take up
AcLDL compared to macrophages also supports the idea that dendritic cells have
increased expression of scavenger receptors than macrophages. Further experiments
need to be done to confirm and identify the role of CD36 or other scavenger receptors,
such as SRA.
The supposition that dendritic cells expressed increased amounts of CD36 suggests the
scavenger receptor functions in immunosurveillance of the local environment.
Scavenger receptors may enable cells to detect increased levels of inflammation signaled
by increased oxidized lipids and bacterial proteins. The scavenger receptor might
provide a way for the immune system to sense "flare-ups" in disease with increased
bacterial load or increased inflammation in local areas. Increased CD36 expression in
LAgP subjects could be another example of ways in which the immune system in patients
with low levels chronic inflammatory disease is primed to respond and is capable of a

heightened response compared to NP subjects. Increased scavenger receptor expression
would also lead to an increased ability to clear oxidized forms of LDL from the
circulation and also the intima of vessel walls. It is possible that in the certain areas of
the body, clearance of LDL is favorable, whereas in the intimal wall and especially
within sites of inflammation, it may lead to foam cell formation and promote
atherogenesis. Atherogenesis is a complex process and fbrther experiments are necessary
to verify a relationship between the chronic inflammation in LAgP, foam cell formation,
and atherosclerosis. It appears that dendritic cell biology is a central component, that
scavenger receptors play a role in linking the host immune and inflammatory responses,
and that the biology of the LAgP myeloid cells is indeed unique.

General Discussion:
The results indicate a unique phenotype of the myeloid cells in LAgP. Further
experiments are necessary but the data here indicate that differential STAT 1 expression
does not contribute to decreased activity of PAFAH expressed by the LAgP nionocytes
In addition PAF synthesis is another manifestation of the unique phenotype of these
LAgP monocytes. Our data support the findings of altered calcium metabolism and
signaling found within the LAgP PMN cells by Van Dyke and others (lo, 3 1-34). The
PMN in LAgP also displays a unique phenotype with increased PAF synthesis. I tis is
possible that other inflammatory lipids, especially those connected to the metabolism of
PAF and the remodeling pathway for PAF synthesis, may also be differentially expressed
in LAgP.
The results here also suggest that the unique phenotype of the LAgP monocyte is
magnified upon culturing cells for 4 days in supplemented cell culture media containing
10% human AB serum. These conditions allow for differentiation of LAgP and NP
monocytes into dendritic cells and macrophages, and result in differential CD36 gene
expression in LAgP compared to NP monocytes. The increase in CD36 expression
suggests the possibility of increased expression of other scavenger receptors involved in
lipid metabolism, and also the possibility of increased expression of other receptors
involved in immunosurveillance, such as pattern-recognition receptors (PRR). These
findings support a model for LAgP in which low-lying levels of bacteria and bacterial
products result in a heightenedlprimed innate immune system compared to NP control
and could possibly result in increased baseline expression of scavenger receptors and
PRR. The end biological effect could be either beneficial or locally toxic to host

tissues/cells depending on bacterial load, tissue health, IgG2 levels and the functional
reserve.
The effect on atherogenesis is also likely to be as complex. However, it does seem
likely that the monocyte is a unique cell capable of crosstalk between the immune and the
inflammatory systems. It also seems likely that the decision to differentiate into a
dendritic cell or macrophage has a significant impact on local disease progression in
terms of influencing antigen presentation, clearance of apoptotic cells, and synthesis or
uptake of inflammatory lipids. In addition, the presence of scavenger receptors on
dendritic cells enables lipids that are chemically modified by reactive oxygen species
(oxidized LDL) to act as a danger signals and activate the immune system in response to
scavenger receptor binding. This could result in increased foam cell formation within the
intima or in hepatic sinusoids and may result in increased clearance of these
inflammatory lipids. Thus, the ultimate effects of the unique phenotype of the myeloid
cells in LAgP remain undetermined and further experiments will be required to further
elucidate the niechanisnis of PAF signaling, monocyte differentiation, and scavenger
receptor biology within these subjects.
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